“By simultaneously targeting WEE1 and YES1 kinases, MRANK-106 has demonstrated remarkable preclinical efficacy in multiple hard-to-treat cancers with limited treatment options. We look forward to ...
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...
"By simultaneously targeting WEE1 and YES1 kinases, MRANK-106 has demonstrated remarkable preclinical efficacy in multiple hard-to-treat cancers with limited treatment options. We look forward to ...
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor ...
The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors. The FDA has cleared the investigational new drug (IND) ...
The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need. Lucid's ...
David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer. David Spigel, MD, ...
This cover highlights the article Multimodal mechanisms of human centriole engagement and disengagement by Kei K. Ito, Shoji Hata, Daiju Kitagawa and colleagues. The cover image depicts the centriole ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback